Phase 2, Double-Blind, Parallel-group Study of S-2367 in Obese Patients with Hypertension and Dyslipidemia

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221085

Enrollment

120

Registered

2010-05-05

Start date

2010-05-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity (BMI: >=25.0) with hypertension and dyslipidemia, except for obesity with diabetes

Interventions

investigational material(s) Generic name etc : S-2367 INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration for Inv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Main inclusion criteria 1. With BMI: >=25.0 2. With visceral fat area >=100 cm2 as determined with abdominal CT 3. Previously diagnosed as hypertension with systolic blood pressure >=140 mmHg or diastolic blood pressure >=90 mmHg 4. Previously diagnosed as dyslipidemia with fasting serum triglycerides >=150 mg/dL and/or fasting serum HDL-cholesterol <40 mg/dL

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Percent change in body weight	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026